BMY Bristol-Myers Squibb
- 59.115
- -0.705-1.18%
Bristol-Myers Squibb News
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
BMO Capital Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $61
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $60
Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
Bristol-Myers Squibb Analyst Ratings
Leerink Partners Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $73
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Jefferies Adjusts Bristol-Myers Squibb Price Target to $63 From $58, Maintains Hold Rating
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $55 From $48
Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $36 From $37, Keeps Underweight Rating
Bristol-Myers Squibb Analyst Ratings
Citi Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Cuts Target Price to $55
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $53
Analysis
Price Target
No Data
No Data
